We also observed that inhibition of ITGB1 with recombinant antibodies prevented lymphangiogenesis and tumor metastasis in EOC, indicating the potential efficacy of anti-ITGB1 therapeutics in EOC. This evidence concerns the gene ITGB1 and neoplasm.